Harmony Biosciences Holdings, Inc. · NASDAQ:HRMY
Harmony Biosciences — Q1 2023 Earnings Presentation
11 slides from Harmony Biosciences's earnings presentation, May 2, 2023
Slide 1: Q1 2023 Financial and Business Update
Q1 2023 Financial and Business Update May 2, 2023
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes forward‐looking statements within the meaning of the Private Securities Reform Act of 1995. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding Harmony Biosciences Hol
Slide 3: Our Corporate Growth Strategy
Our Corporate Growth Strategy Optimize WAKIX® Expand Clinical Utility of Acquire Performance Pitolisant New Assets DESIGNED TO SUPPORT LONG TERM SUSTAINABLE GROWTH 3
Slide 4: WAKIX Net Revenue Performance
WAKIX® Net Revenue Performance CONFIDENT IN WAKIX BECOMING A POTENTIAL $1B+ NARCOLEPSY OPPORTUNITY, WITH THE POTENTIAL TO CONTRIBUTE UP TO AN ADDITIONAL $1B, IF APPROVED IN IDIOPATHIC HYPERSOMNIA AND OTHER CURRENT LIFECYCLE MANAGEMENT PROGRAMS WAKIX QUARTERLY NET REVENUE ($M) HIGHLIGHTS 40% ▪ Strong
Slide 5: Driving Growth Through Strong Commercialization of WAKIX
Driving Growth Through Strong Commercialization of WAKIX® Q1 2023 Performance >80% ~5,100 U.S. Covered Lives With Average # of Formulary Access Patients on WAKIX Continued Growth in Depth & Breadth of Prescriber Base ~85% In-Person Access to HCPs 5
Slide 6: Development Pipeline
Development Pipeline Regulatory Marketed Product / Indication Pre-IND Phase 1 Phase 2 Phase 3 Filing1 Milestone Product WAKIX® EDS in Narcolepsy (Adults) Cataplexy in Narcolepsy (Adults) Pitolisant EMA Approval Pediatric Narcolepsy2 1Q2023 Idiopathic Hypersomnia Topline data (IH) 4Q2023 Prader-Willi
Slide 7: Financial Highlights
Financial Highlights (In millions, USD) Net Product Non-GAAP Adjusted Revenues Net Income(1) 40% 29% $119.1 $85.3 $31.1 $40.1 Q1 2022 Q1 2023 Q1 2022 Q1 2023 Cash, Cash Equivalents & Investment Securities $392.4 $316.0 $345.7 $258.9 $224.5 Mar 31 '22 Jun 30 '22 Sep 30 '22 Dec 31 '22 Mar 31 '23 (1) N
Slide 8: Financial Summary
Financial Summary (In millions, USD) Three Months Ended March 31, % Change Totals may not foot due to rounding 2023 2022 Net Product Revenues $119.1 $85.3 40% Cost of Product Sold 20.8 14.7 41% Total Operating Expenses $57.9 $43.0 35% R&D Expense 13.3 7.6 75% S&M Expense 22.6 17.6 28% G&A Expense 22
Slide 9: GAAP vs NON-GAAP Reconciliation
GAAP vs NON-GAAP Reconciliation (In millions, USD) Three Months Ended March 31, Totals may not foot due to rounding 2023 2022 GAAP net income $29.5 $21.5 Non-cash interest expense(1) 0.4 0.4 Depreciation 0.1 0.1 Amortization(2) 6.0 5.1 Stock-based compensation expense 6.6 4.9 Income tax effect relat
Slide 10: Harmony Continues To Be A Growth Story
Harmony Continues To Be A Growth Story Strong Commercial Poised to Extend Pitolisant Performance & Future Value Proposition Beyond Growth of WAKIX in Narcolepsy with IH, PWS Narcolepsy & DM New Development Talented Team & Programs to Expand Solid Balance Sheet Portfolio, Treatment Positioned for Nex
Slide 11: Thank You
H3 HARMONY BIOSCIENCES Thank You
Harmony Biosciences Holdings — Q1 2023 Earnings Presentation on 6ix